Citius Pharmaceuticals, Inc. (CTXR) Earnings History
Net Loss15 years of earnings data (2011–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Citius Pharmaceuticals, Inc. (CTXR) Earnings Overview
As of June 23, 2026, Citius Pharmaceuticals, Inc. (CTXR) reported trailing twelve-month net income of -$46M, reflecting +43.4% year-over-year growth. The company earned $-2.06 per diluted share over the past four quarters.
Looking at the long-term picture, CTXR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$22,006 in fiscal 2012.
Citius Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTR (-$158M net income, -297.1% margin), HALO ($349M net income, 22.7% margin), PRGO (-$1.82B net income, -33.5% margin), CTXR has comparable earnings metrics. Compare CTXR vs NKTR →
CTXR Earnings vs Peers
Earnings metrics vs comparable public companies
CTXR Historical Earnings Data (2011–2025)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$37M | +4.4% | -$39M | $-3.38 | - | - |
| 2024 | -$39M | -20.3% | -$42M | $-5.97 | - | - |
| 2023 | -$33M | +3.3% | -$37M | $-5.57 | - | - |
| 2022 | -$34M | -45.5% | -$33M | $-5.76 | - | - |
| 2021 | -$23M | -31.8% | -$24M | $-5.64 | - | - |
| 2020 | -$18M | -12.6% | -$18M | $-0.45 | - | - |
| 2019 | -$16M | -24.3% | -$16M | $-0.77 | - | - |
| 2018 | -$13M | -20.7% | -$14M | $-1.17 | - | - |
| 2017 | -$10M | -25.2% | -$10M | $-1.89 | - | - |
| 2016 | -$8M | -185.8% | -$7M | $-2.29 | - | - |
| 2015 | -$3M | -128.1% | -$3M | $-1.37 | - | - |
| 2014 | -$1M | -3955.4% | -$1M | $-0.95 | - | - |
| 2013 | $-31,369 | -42.5% | $-28,118 | $-0.04 | - | - |
| 2012 | $-22,006 | +16.5% | $-19,618 | $-0.03 | - | - |
| 2011 | $-26,341 | - | $-25,637 | $-0.04 | - | - |
Download Data
Export CTXR earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CTXR — Frequently Asked Questions
Quick answers to the most common questions about buying CTXR stock.
What is CTXR earnings per share (EPS)?
CTXR trailing twelve-month (TTM) diluted EPS is $-2.06, reflecting +43.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2025 is available in the table on this page.
What is Citius Pharmaceuticals, Inc.'s net income?
Citius Pharmaceuticals, Inc. (CTXR) trailing twelve-month net income is $-46M as of 2025. Earnings grew +43.4% year-over-year.
Is CTXR profitable?
CTXR is not currently profitable on a TTM basis, reporting a net loss of $-46M. Net margin is N/A. Investors should monitor for a return to profitability.
What is CTXR's earnings growth rate?
CTXR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2025.
What are CTXR's profit margins?
Citius Pharmaceuticals, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -49.4%.
Is CTXR growing earnings?
Yes, CTXR earnings are accelerating — EPS growth of +43.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-46M. Earnings momentum is strengthening.
What was CTXR's best earnings year?
Citius Pharmaceuticals, Inc.'s highest annual net income on record is $-22006.00, achieved in fiscal year 2012. Earnings history on this page spans 2011 to 2025 and includes all annual and quarterly figures.
What were CTXR's earnings last quarter?
CTXR's most recent reported quarter was Q2 2026. Net income was $-21M with diluted EPS of $-0.95. For a full breakdown of all quarters, see the quarterly earnings table on this page.